XDH and gout: With regard to xanthine oxidase inhibitors (allopurinol, febuxostat), the ALL-HEARTstudy, a multicentre, prospective, randomised, open-label, blinded-endpoint trial, 5,937 patients with ischemic heart disease but no history of gout were randomly assigned to receive allopurinol or usual care (51).